EPCAM and prostate cancer: In prostate cancer, a subanalysis indicated that EpCAM expression is higher on hormone-refractory tumour tissue than on earlier stages (P=0.015), and that there is a decrease in EpCAM expression with increasing Gleason score (P=0.011).